Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio

 

 

 

 

 

Crescita Therapeutics Inc. (TSX: CTX), a Canadian commercial dermatology company and Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development,  today announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer (“MMPE™”) and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene which is known to work on Cannabidiol 2 receptors. The testing methodology and the clinical development made possible by the collaboration will help optimize the delivery of Beta-C and several other active ingredients into the skin and local tissues.

 

Some of Tetra’s dermatology products have already been approved by Health Canada as natural health products, and address several medical conditions, including but not limited to, muscle and joint pain, cold sores and hemorrhoids. In late 2018, Crescita published the favorable results of a study demonstrating the enhanced permeation of CBD, the non-psychoactive component of cannabis. The in-vitro skin permeation study showed that both MMPE and DuraPeel significantly increased the transdermal permeation of CBD over the control formulation by up to 14- and 6-fold, respectively. Based on these results, Tetra believes that the use of Crescita’s patented technologies will improve the permeability and potentially, the efficacy of Beta-C and will enhance the intellectual property of its dermatology portfolio.

 

In addition, the companies have entered into discussions related to Crescita’s contract manufacturing services to produce Tetra’s enhanced product portfolio once the desired results have been attained in the development and testing phases of the collaboration.

 

We are excited to partner with Tetra Natural Health, another home-grown Canadian Company and to assist them in the development and evaluation of several enhanced-delivery formats of their topical products,” said Serge Verreault, President and Chief Executive Officer of Crescita. “By integrating Crescita’s patented MMPE and DuraPeel technologies into their existing formulations, we believe we will be able to significantly enhance the delivery and related efficacy of their products which will help improve outcomes for Canadians suffering from a variety of painful conditions,” added Mr. Verreault.

 

This new collaborative agreement signed with Crescita will allow Tetra Natural Health to address many Canadian patients’ dermatology needs. Crescita’s technology is outstanding and we believe it will set our natural health dermatology portfolio apart from our competition. Not only will it improve permeability of our Beta C derived products, but it may also improve their efficacy.” said Richard Giguère, Chief Executive Officer of Tetra Natural Health.

 

About Crescita Therapeutics Inc.

 

Crescita is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. 

 

About Tetra Natural Health

 

Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc. and focuses on the identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoid-derived products authorized for sale by Health Canada.

 

About Tetra Bio-Pharma

 

Tetra Bio-Pharma a biopharmaceutical leader in cannabinoid-derived drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

 

About MMPE™

 

The MMPE technology uses synergistic combinations of pharmaceutical excipients included on the FDA’s Inactive Ingredient Guide for improved topical delivery of active pharmaceutical ingredients (APIs) into or through the skin. The benefits of this technology include the potential for increased penetration of APIs with the possibility of improved efficacy, lower API concentration and/or reduced dosing. Issued U.S. patents provide intellectual property protection through March 6, 2027.

 

About DuraPeel™

 

The DuraPeel technology is a self-occluding, film-forming cream/gel formulation that provides extended release delivery to the site of application. The cream/gel contains a drug applied to a patient’s skin forming a pliable layer that releases drug into the skin for up to 12 hours. The benefits of the DuraPeel technology include proven compatibility with a variety of active pharmaceutical ingredients (“APIs”). A self-occluding film reduces product transference risk, provides fast drying time, facilitates easy application and removal, and enables application to large and irregular skin surfaces. Patents have been issued in Australia, Canada, Japan and the U.S. with the latest expiry in 2027. The European patent application is still pending.

 

Posted February 4, 2019

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

MORE or "UNCATEGORIZED"


Heuro Canada announces Western Canada's first Heuro PoNS™ treatment centre

Heuro Canada Inc., a leading provider of innovative neurological ... READ MORE

February 21, 2019

ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies

IMMUNOPRECISE ANTIBODIES LTD. (TSX-V: IPA) (OTC PINK: IPATF) ... READ MORE

February 21, 2019

Kneat and HCL Technologies Partner to Deliver Digital Validation Solutions to Life Sciences

kneat.com, inc. (TSX-V: KSI) is pleased to announce that it has s... READ MORE

February 21, 2019

Terramera secures USD $10 million in financing from BDC

BDC will provide $13 million (USD $10 million) in growth capital ... READ MORE

February 21, 2019

Kneat Announces Closing of $6,339,375 Public Equity Financing and Concurrent $2,178,159 Non-Brokered Private Placement Equity Financing

kneat.com, inc. (TSXV: KSI) is pleased to announce that it has cl... READ MORE

February 20, 2019

Copyright 2019 The Venture Report